EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of [18F]PSMA‐1007 uptake variability in patients with prostate cancer

Elin Trägårdh iD, Måns Larsson iD, David Minarik iD, Olof Enqvist iD, Lars Edenbrandt

Clinical Physiology and Functional Imaging · 2025

DOI: 10.1111/cpf.70016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Physiology and Functional Imaging, 2025. Verfasst von Elin Trägårdh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals, Oligopeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Knut and Alice Wallenberg Foundation, Medical Faculty at Lund University, Region Skåne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The biodistribution of PSMA‐ligands is of interest in radionuclide therapy planning. We investigated the variability of [ 18 F]PSMA‐1007 uptake in organs at risk and in relation to tumour burden in prostate cancer patients.

Methods

A total of 1086 patients who underwent PSMA PET‐CT for staging or recurrence of prostate cancer were included. Total lesion volume (TLV) and total lesion uptake (TLU) were calculated from manual segmentations. The mean standardized uptake value (SUV mean ) in the organs at risk kidneys, liver, parotid glands and spleen was obtained. Correlations between TLV/TLU and SUV mean in normal tissues were calculated using Spearman rank correlation. SUV mean in normal tissues was stratified into groups based on TLV.

Results

The median (IQR) SUV mean of the kidneys, liver, parotid glands, and spleen was 13.1 (IQR 4.6), 11.8 (4.4), 18.6 (6.8) and 11.3 (5.8), respectively. The median TLV was 3.8 cm 3 (9.7) and median TLU was 31.2 cm 3 (106.3). There was no significant correlation between TLV or TLU and SUV mean for the liver, parotid glands, or spleen, but a weak negative correlation between TLV/TLU and SUV mean in the kidneys ( r = −0.011, p = 0.0005; r = −0.09, p = 0.003). There was a tendency towards a lower SUV mean in the kidneys and parotid glands in patients with a very high TLV.

Conclusions

There was a large uptake variability in organs at risk, which demonstrates the need for individual pretherapy dosimetry. There may be a tumour sink effect in the kidneys and parotid glands in patients with a very high TLV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyRadiopharmaceuticalsOligopeptidesFluorine RadioisotopesHumansMaleAgedTissue DistributionMiddle AgedTumor BurdenRetrospective StudiesOrgans at RiskNeoplasm StagingPredictive Value of TestsNiacinamide

Stichwörter der Autor:innen

PET, tumour sink effectPSMA[18F]PSMA−1007prostate cancerradioligand therapy

Substanzen

RadiopharmaceuticalsPSMA-1007OligopeptidesFluorine RadioisotopesNiacinamide

Autor:innen und Institutionen

  • Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, Sweden.
  • Department of Translational Medicine and Wallenberg Center for Molecular Medicine, Lund University, Malmö, Sweden.
  • Eigenvision AB, Malmö, Sweden.
  • Department of Radiation Physics, Skåne University Hospital, Malmö, Sweden.
  • Chalmers University of Technology, Gothenburg, Sweden.
  • Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

ORCID-Profile: Elin Trägårdh, Måns Larsson, David Minarik, Olof Enqvist

Förderung

  • Knut and Alice Wallenberg Foundation
  • Medical Faculty at Lund University
  • Region Skåne
  • Malmö General Hospital Foundation
  • Swedish Cancer Foundation
  • Swedish Prostate Cancer Foundation

Zitieren

APA

Trägårdh, E., Larsson, M., Minarik, D., Enqvist, O., & Edenbrandt, L. (2025). Evaluation of [18F]PSMA‐1007 uptake variability in patients with prostate cancer. Clinical Physiology and Functional Imaging. https://doi.org/10.1111/cpf.70016

Vancouver

Trägårdh E, Larsson M, Minarik D, Enqvist O, Edenbrandt L. Evaluation of [18F]PSMA‐1007 uptake variability in patients with prostate cancer. Clinical Physiology and Functional Imaging. 2025. doi:10.1111/cpf.70016

BibTeX
@article{Trgrdh2025,
  author = {Trägårdh, Elin and Larsson, Måns and Minarik, David and Enqvist, Olof and Edenbrandt, Lars},
  title = {Evaluation of [18F]PSMA‐1007 uptake variability in patients with prostate cancer},
  journal = {Clinical Physiology and Functional Imaging},
  year = {2025},
  doi = {10.1111/cpf.70016}
}
Kostenlos starten →